A Phase 1/2 interventional study of nivolumab and rHuPH20 in Neoplasms by Site, sponsored by Bristol-Myers Squibb. Completed at 36 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies in Neoplasms by Site with a site in United States — 31 open to participants now, 44 under way, 7 of them phase 3. Neoplasms by Site · United States.
Among the 119 studies in Neoplasms by Site with a site in United States, this one is the 44th largest by enrollment of the 102 interventional ones that give a count, is one of 6 that started in 2018, is one of 23 in phase 1/2, and was the 61st registered.
208 studies on the registry are indexed under Neoplasms by Site; 53 are open to participants now.
Browse Neoplasms by Site studies →31 of the 119 studies in Neoplasms by Site with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, France, Germany and 6 more countries
Ages 18–130
Astellas Pharma Global Development, Inc. · Sites in United States, Canada, Korea, Republic of and 1 more country
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 14 more countries
Ages 18+
Orca Biosystems, Inc. · Sites in United States
Ages 18+
K36 Therapeutics, Inc. · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Neoplasms by Site studies recruiting now, 40 (78%) set no upper age limit and 6 (12%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 41 · Phase 3 21 · Phase 4 3
First in 2003; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 88 across 171 interventional studies indexed under Neoplasms by Site.
Median enrollment 102 across the 102 interventional studies, 440 across the 17 observational. Of the 70 that completed or were terminated, 40 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 119 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 5 studies filed under Neoplasms by Site — fewer than ten, so there is no comparison to draw.
17 of the studies in Neoplasms by Site with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT05664243In8bio Inc.A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | 2026-12 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT06463665Genelux CorporationEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | 2027-02 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 119 studies in Neoplasms by Site with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20.
This study will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Histologic or cytologic confirmation of advanced ( and/or unresectable) solid tumors of one of the following tumor types:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: nivolumab · Drug: rHuPH20
Biological: nivolumab · Drug: rHuPH20
Biological: nivolumab
Biological: nivolumab
Biological: nivolumab · Drug: rHuPH20
Biological: nivolumab · Drug: rHuPH20
Biological: nivolumab · Drug: rHuPH20
Maximum Observed Serum Nivolumab Concentration (Cmax) - Parts A, B, D, and E
Cmax is the maximum observed serum nivolumab concentration. Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.
Time frame: From first dose until approximately 21 days post first dose.
Time Taken to Reach Cmax (Tmax) - Parts A, B, D, and E
Tmax is the time taken to reach the maximum observed serum nivolumab concentration (Cmax). Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.
Time frame: From first dose until approximately 21 days post first dose.
Area Under the Time-Serum Nivolumab Concentration Curve (AUC (TAU)) - Parts A, B, D, and E
AUC (TAU) is the area measured under the concentration-time curve taken over the dosing interval. Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.
Time frame: From first dose until approximately 21 days post first dose.
Observed Serum Nivolumab Concentration at the End of Dosing (Ctau) - Parts A, B, D, and E
Ctau is the observed serum nivolumab concentration at the end of the dosing interval. Collected for Arma A, B, and D.
Time frame: At the end of dosing interval of Cycle 1 - first dose (Day 21 for Parts A, B and D; Day 15 for Part E)
Lowest Observed Serum Nivolumab Concentration (Ctrough) During Part C - Part A and B Crossover Participants to Part C
Ctrough assessed during Part C. Ctrough is the lowest observed serum nivolumab concentration.
Time frame: On Day 1 of Cycles 2, 3, 5, 9, 13, and 19 of Part C (Day 1 of Part C: up to 14 months from Baseline; each cycle was 28 days)
Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose until 100 days post last dose (up to approximately 70 months).
Number of Participants Experiencing Treatment Related Adverse Events (TRAEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TRAEs are AEs where a reasonable causal relationship exists between study treatment administration and the AE.
Time frame: From first dose until 100 days post last dose (up to approximately 70 months).
Number of Participants Experiencing Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: (a) results in death, (b) is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), and/ or (c) requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose until 100 days post last dose (up to approximately 70 months).
Number of Participants Experiencing Treatment Related Serious Adverse Events (TRSAEs)
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: (a) results in death, (b) is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), and/ or (c) requires inpatient hospitalization or causes prolongation of existing hospitalization. TRSAEs are SAEs where a reasonable causal relationship exists between study treatment administration and the SAE.
Time frame: From first dose until 100 days post last dose (up to approximately 70 months).
Number of Participants Experiencing Treatment Related Adverse Events (TRAEs) Leading to Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TRAEs are AEs where a reasonable causal relationship exists between study treatment administration and the AE.
Time frame: From first dose until 100 days post last dose (up to approximately 70 months).
Number of Participants Who Died
Number of participants who died due to any cause.
Time frame: From randomization until data cutoff (up to approximately 70 months).
Number of Participants With Select Laboratory Changes From Baseline
Laboratory parameters including hematology, chemistry, liver function, and renal function summarized using worst grade NCI CTCAE v.5 criteria. Baseline refers to evaluations with a date on or prior to the day of first dose of study treatment.
Time frame: From first dose until 30 days post last dose (up to approximately 67 months and 20 days).
Number of Participants Experiencing Any Select Adverse Events Within the Hypersensitivity/Infusion Reaction Category and Broad Standardized MedDRA Query (SMQ) of Anaphylactic Reaction Occurring Within 2 Days of Study Drug Administration
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: From first dose until 2 days post last dose (up to approximately 66 months and 22 days).
Number of Participants With Anti-Nivolumab Antibodies (ADAs) and Neutralizing Antibodies
Anti-drug antibody (ADA) Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment; Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline. Baseline ADA Positive: A participant with a baseline ADA-positive sample. Baseline refers to evaluations with a date on or prior to the day of first dose of study treatment.
Time frame: At baseline and up to 100 days post last dose (up to approximately 70 months).
| Milestone | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab SC + rHuPH20 1200 mg Q4W | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Started | 22 | 18 | 10 | 17 | 0 | 36 | 36 |
| Completed | 22 | 18 | 10 | 17 | 0 | 36 | 36 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab SC + rHuPH20 1200 mg Q4W | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Started | 22 | 18 | 10 | 17 | 0 | 36 | 36 |
| Completed | 10 | 6 | 5 | 9 | 0 | 7 | 6 |
| Not completed | 12 | 12 | 5 | 8 | 0 | 29 | 30 |
| Withdrew: Disease progression | 8 | 11 | 4 | 6 | 0 | 20 | 21 |
| Withdrew: Study drug toxicity | 2 | 1 | 1 | 2 | 0 | 4 | 1 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 0 | 0 | 0 | 4 | 1 |
| Withdrew: Participant requested to discontinue study treatment | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Milestone | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab SC + rHuPH20 1200 mg Q4W | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 28 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 12 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 16 | 0 | 0 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 12 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Participant requested to discontinue study treatment | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Maximum clinical benefit | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Cmax is the maximum observed serum nivolumab concentration. Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.
| ug/mL | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|
| Maximum Observed Serum Nivolumab Concentration (Cmax) - Parts A, B, D, and E | 54.8 ± 51.0 | 56.6 ± 34.0 | 81.4 ± 41.0 | 63.9 ± 30.0 | 106.0 ± 46.0 | 57.8 ± 31.0 |
Tmax is the time taken to reach the maximum observed serum nivolumab concentration (Cmax). Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.
| hours | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|
| Time Taken to Reach Cmax (Tmax) - Parts A, B, D, and E | 167 (47.0 to 357.0) | 167 (50.1 to 339.0) | 141 (47.2 to 333.0) | 168 (139.0 to 355.0) | 130 (44.5 to 317.0) | 130 (45.2 to 337.0) |
AUC (TAU) is the area measured under the concentration-time curve taken over the dosing interval. Collected for Arm A, B, and D on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15, and Cycle 1 Day 21. Collected for Arm E on Cycle 1 Day 1, Cycle 1 Day 2, Cycle 1 Day 4, Cycle 1 Day 8, Cycle 1 Day 15.
| h*ug/mL | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|
| Area Under the Time-Serum Nivolumab Concentration Curve (AUC (TAU)) - Parts A, B, D, and E | 24908 ± 53 | 27909 ± 36 | 40264 ± 45 | 32702 ± 31 | 53561 ± 40 | 15857 ± 30 |
Ctau is the observed serum nivolumab concentration at the end of the dosing interval. Collected for Arma A, B, and D.
| ug/mL | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|
| Observed Serum Nivolumab Concentration at the End of Dosing (Ctau) - Parts A, B, D, and E | 22.2 ± 86 | 26.9 ± 65 | 39.2 ± 67 | 34.8 ± 41 | 54.4 ± 49 | 43.6 ± 36 |
Ctrough assessed during Part C. Ctrough is the lowest observed serum nivolumab concentration.
| ug/mL | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg |
|---|---|---|---|---|
| Cycle 2 Day 1 | 115 ± 58 | 106 ± 42 | 124 ± 38 | 85.7 ± 48 |
| Cycle 3 Day 1 | 119 ± 51 | 118 ± 34 | 149 ± 42 | 104 ± 44 |
| Cycle 5 Day 1 | 149 ± 55 | 144 ± 66 | 192 ± 16 | 171 ± 8 |
| Cycle 9 Day 1 | 170 ± 55 | 138 ± 81 | 228 ± NA | 208 ± 38 |
| Cycle 13 Day 1 | 183 ± 34 | 113 ± 48 | 246 ± NA | 217 ± 16 |
| Cycle 19 Day 1 | — | 74.7 ± NA | — | 212 ± NA |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 22 | 18 | 10 | 17 | 27 | 36 | 36 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TRAEs are AEs where a reasonable causal relationship exists between study treatment administration and the AE.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Treatment Related Adverse Events (TRAEs) | 14 | 10 | 8 | 11 | 16 | 27 | 28 |
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: (a) results in death, (b) is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), and/ or (c) requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Serious Adverse Events (SAEs) | 12 | 10 | 4 | 11 | 11 | 19 | 25 |
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: (a) results in death, (b) is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), and/ or (c) requires inpatient hospitalization or causes prolongation of existing hospitalization. TRSAEs are SAEs where a reasonable causal relationship exists between study treatment administration and the SAE.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Treatment Related Serious Adverse Events (TRSAEs) | 1 | 1 | 0 | 2 | 0 | 3 | 1 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TRAEs are AEs where a reasonable causal relationship exists between study treatment administration and the AE.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Treatment Related Adverse Events (TRAEs) Leading to Discontinuation | 2 | 1 | 1 | 2 | 0 | 4 | 2 |
Number of participants who died due to any cause.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Died | 18 | 14 | 8 | 14 | 17 | 25 | 30 |
Laboratory parameters including hematology, chemistry, liver function, and renal function summarized using worst grade NCI CTCAE v.5 criteria. Baseline refers to evaluations with a date on or prior to the day of first dose of study treatment.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| HEMOGLOBIN (g/L) | 13 | 7 | 3 | 8 | 15 | 12 | 12 |
| PLATELET COUNT (10^9/L) | 2 | 5 | 0 | 2 | 5 | 6 | 4 |
| LEUKOCYTES, LOCAL LAB (10^9/L) | 1 | 5 | 1 | 1 | 7 | 3 | 3 |
| ABSOLUTE NEUTROPHIL COUNT DRV. (10^9/L) | 2 | 2 | 1 | 2 | 5 | 2 | 3 |
| LYMPHOCYTES (ABSOLUTE) (10^9/L) | — | 3 | — | 2 | 2 | 2 | 3 |
| LYMPHOCYTES (ABSOLUTE), LOCAL LAB (10^9/L) | 10 | 9 | 5 | 5 | 12 | 7 | 16 |
| CREATININE, LOCAL LAB (umol/L) | 7 | 1 | 3 | 2 | 8 | 8 | 12 |
| ALKALINE PHOSPHATASE (ALP) LOCAL LAB (U/L) | 7 | 6 | 3 | 9 | 8 | 18 | 20 |
| ALANINE AMINOTRANSFERASE (ALT), LOCAL LAB (U/L) | 6 | 8 | 3 | 7 | 9 | 7 | 11 |
| ASPARTATE AMINOTRANSFERASE (AST), LOCAL LAB (U/L) | 5 | 9 | 4 | 6 | 6 | 11 | 14 |
| BILIRUBIN, TOTAL, LOCAL LAB (umol/L) | 2 | 6 | 1 | 2 | 5 | 4 | 6 |
| HYPERCALCEMIA (mmol/L) | 1 | 1 | 1 | 2 | 2 | 6 | 3 |
| HYPERKALEMIA (mmol/L) | 7 | 4 | 4 | 2 | 9 | 7 | 9 |
| HYPERMAGNESEMIA (mmol/L) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERNATREMIA (mmol/L) | 2 | 1 | 1 | 2 | 5 | 4 | 3 |
| HYPOCALCEMIA (mmol/L) | 5 | 2 | 2 | 2 | 2 | 4 | 5 |
| HYPOKALEMIA (mmol/L) | 1 | 1 | 1 | 1 | 3 | 3 | 5 |
| HYPOMAGNESEMIA (mmol/L) | 5 | 1 | 1 | 3 | 3 | 2 | 2 |
| HYPONATREMIA (mmol/L) | 8 | 4 | 5 | 3 | 9 | 9 | 13 |
| HYPOGLYCEMIA (mmol/L) | 1 | 1 | 0 | 1 | 2 | 2 | 1 |
| ALBUMIN, LOCAL LAB (g/L) | 6 | 6 | 3 | 2 | — | 13 | 5 |
| ACTIVATED PARTIAL THROMBOPLASTIN TIME (sec) | 1 | 2 | — | 1 | — | 2 | 1 |
| FIBRINOGEN (g/L) | 0 | 0 | — | 0 | — | 0 | 0 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| Nivolumab administered subcutaneously (SC) +/- rHuPH20 | 1 | 1 | 0 | 0 | 4 | 3 | 8 |
| Nivolumab administered intravenously (IV) | 2 | 2 | 1 | 2 | — | — | — |
Anti-drug antibody (ADA) Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment; Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline. Baseline ADA Positive: A participant with a baseline ADA-positive sample. Baseline refers to evaluations with a date on or prior to the day of first dose of study treatment.
| Participants | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part C - Nivolumab + rHuPH20 SC 1200mg Q4W (Crossover Participants From Parts A and B) | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|
| ANTI-DRUG ANTIBODY (ADA) POSITIVE | 7 | 5 | 3 | 0 | 7 | 5 | 10 |
| NEUTRALIZING POSITIVE | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BASELINE ANTI-DRUG ANTIBODY (ADA) POSITIVE | 2 | 0 | 2 | 0 | 2 | 1 | 1 |
Collected over All-cause Mortality was collected from randomization until the data cutoff date (approximately 70 months). SAEs and Other AEs were collected from the first dose until 100 days post the last dose (up to approximately 70 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | 18/22 (81.8%) | 12/22 (54.5%) | 22/22 (100%) |
| PART A - GRP 1 CROSSOVER to PART C | 6/9 (66.7%) | 4/9 (44.4%) | 9/9 (100%) |
| Part B - Group 2: Nivolumab SC 720mg | 14/18 (77.8%) | 10/18 (55.6%) | 18/18 (100%) |
| PART B - GRP 2 CROSSOVER to PART C | 2/6 (33.3%) | 1/6 (16.7%) | 6/6 (100%) |
| Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | 8/10 (80%) | 4/10 (40%) | 10/10 (100%) |
| PART B - GRP 3 CROSSOVER to PART C | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| Part B - Group 4: Nivolumab SC 960mg | 14/17 (82.4%) | 11/17 (64.7%) | 17/17 (100%) |
| PART B - GRP 4 CROSSOVER to PART C | 5/8 (62.5%) | 4/8 (50%) | 8/8 (100%) |
| Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | 25/36 (69.4%) | 19/36 (52.8%) | 34/36 (94.4%) |
| Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W | 30/36 (83.3%) | 25/36 (69.4%) | 35/36 (97.2%) |
| Event | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | PART A - GRP 1 CROSSOVER to PART C | Part B - Group 2: Nivolumab SC 720mg | PART B - GRP 2 CROSSOVER to PART C | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | PART B - GRP 3 CROSSOVER to PART C | Part B - Group 4: Nivolumab SC 960mg | PART B - GRP 4 CROSSOVER to PART C | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/22 | 0/9 | 0/18 | 0/6 | 2/10 | 2/5 | 3/17 | 2/8 | 0/36 | 2/36 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/22 | 1/9 | 5/18 | 0/6 | 0/10 | 0/5 | 4/17 | 1/8 | 4/36 | 7/36 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 0/22 | 0/9 | 0/18 | 0/6 | 1/10 | 1/5 | 0/17 | 0/8 | 0/36 | 0/36 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/22 | 0/9 | 1/18 | 0/6 | 1/10 | 1/5 | 0/17 | 0/8 | 0/36 | 0/36 |
| HypotensionVascular disorders | 0/22 | 0/9 | 0/18 | 0/6 | 1/10 | 1/5 | 0/17 | 0/8 | 0/36 | 0/36 |
| CholangitisHepatobiliary disorders | 0/22 | 0/9 | 2/18 | 1/6 | 0/10 | 0/5 | 1/17 | 1/8 | 0/36 | 0/36 |
| CholelithiasisHepatobiliary disorders | 0/22 | 0/9 | 1/18 | 1/6 | 0/10 | 0/5 | 0/17 | 0/8 | 0/36 | 0/36 |
| Rectal haemorrhageGastrointestinal disorders | 0/22 | 0/9 | 0/18 | 0/6 | 0/10 | 0/5 | 1/17 | 1/8 | 0/36 | 0/36 |
| Urinary tract infectionInfections and infestations | 1/22 | 0/9 | 0/18 | 0/6 | 0/10 | 0/5 | 1/17 | 1/8 | 1/36 | 0/36 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 0/22 | 0/9 | 0/18 | 0/6 | 0/10 | 0/5 | 1/17 | 1/8 | 0/36 | 0/36 |
| Event | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | PART A - GRP 1 CROSSOVER to PART C | Part B - Group 2: Nivolumab SC 720mg | PART B - GRP 2 CROSSOVER to PART C | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | PART B - GRP 3 CROSSOVER to PART C | Part B - Group 4: Nivolumab SC 960mg | PART B - GRP 4 CROSSOVER to PART C | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 4/22 | 2/9 | 1/18 | 1/6 | 6/10 | 4/5 | 2/17 | 2/8 | 6/36 | 1/36 |
| DiarrhoeaGastrointestinal disorders | 5/22 | 2/9 | 4/18 | 3/6 | 1/10 | 1/5 | 4/17 | 2/8 | 4/36 | 6/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/22 | 4/9 | 2/18 | 2/6 | 0/10 | 0/5 | 5/17 | 2/8 | 5/36 | 10/36 |
| AnaemiaBlood and lymphatic system disorders | 5/22 | 1/9 | 6/18 | 1/6 | 3/10 | 2/5 | 2/17 | 1/8 | 3/36 | 7/36 |
| AstheniaGeneral disorders | 5/22 | 2/9 | 7/18 | 2/6 | 0/10 | 0/5 | 2/17 | 1/8 | 2/36 | 8/36 |
| Back painMusculoskeletal and connective tissue disorders | 4/22 | 1/9 | 0/18 | 0/6 | 1/10 | 1/5 | 3/17 | 3/8 | 5/36 | 5/36 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/22 | 2/9 | 1/18 | 0/6 | 0/10 | 0/5 | 4/17 | 3/8 | 3/36 | 4/36 |
| HypothyroidismEndocrine disorders | 2/22 | 2/9 | 2/18 | 2/6 | 0/10 | 0/5 | 1/17 | 1/8 | 8/36 | 8/36 |
| Dry mouthGastrointestinal disorders | 1/22 | 1/9 | 3/18 | 2/6 | 0/10 | 0/5 | 1/17 | 0/8 | 0/36 | 4/36 |
| VomitingGastrointestinal disorders | 4/22 | 1/9 | 2/18 | 2/6 | 0/10 | 0/5 | 3/17 | 1/8 | 3/36 | 2/36 |
Participants in Part C are presented under their original treatment assignment.
| Age, Categorical(Participants) | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 12 | 5 | 6 | 14 | 19 | 62 |
| >=65 years | 16 | 6 | 5 | 11 | 22 | 17 | 77 |
| Sex: Female, Male(Participants) | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W | Total |
|---|---|---|---|---|---|---|---|
| Female | 12 | 5 | 6 | 5 | 10 | 9 | 47 |
| Male | 10 | 13 | 4 | 12 | 26 | 27 | 92 |
| Ethnicity (NIH/OMB)(Participants) | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 4 | 1 | 6 |
| Not Hispanic or Latino | 4 | 5 | 2 | 7 | 16 | 22 | 56 |
| Unknown or Not Reported | 17 | 13 | 8 | 10 | 16 | 13 | 77 |
| Race/Ethnicity, Customized(Participants) | Part A - Group 1: Nivolumab + rHuPH20 SC 720mg | Part B - Group 2: Nivolumab SC 720mg | Part B - Group 3: Nivolumab + rHuPH20 SC 960mg | Part B - Group 4: Nivolumab SC 960mg | Part D: Nivolumab SC + rHuPH20 SC 1200mg Q4W | Part E: Nivolumab SC Co-Formulated With rHuPH20 600mg Q2W | Total |
|---|---|---|---|---|---|---|---|
| White | 18 | 18 | 8 | 17 | 31 | 34 | 126 |
| Black or African American | 2 | 0 | 0 | 0 | 1 | 0 | 3 |
| Other | 2 | 0 | 2 | 0 | 3 | 1 | 8 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Sep 2022, 46 months.
Results were first posted in Feb 2025, 2 years 5 months after primary completion. A results delay was requested in Mar 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab